Immunotech Completes Merger Acquisition

GLENDALE, Calif., March 30 /PRNewswire-FirstCall/ -- Immunotech Laboratories,
Inc.(Pink Sheets: IMMB) has completed a reverse merger with a public shell
company and has restructured its position through a 100 to 1 reverse split of
stock. The company has issued 60 million authorized shares bringing the total
number of issued and outstanding shares to 60,555,688 shares trading under
NASDAQ OTC.PK Exchange ticker symbol IMMB.

Immunotech Laboratories, Inc. has indefinite licensing rights of the
Irreversible Pepsin Fraction (IPF) peptide molecule for the specific treatment
of the HIV/AIDS indication. IPF has demonstrated to have both fusion
inhibitor and immunomodulator capabilities during in vitro studies with no
viral resistance. This provides opportunities for patients that have already
shown resistance to one or more antiretroviral therapies.

Immunotech Laboratories' core competency is in developing novel therapeutic
molecules for the treatment of HIV/AIDS and a research pipeline with potential
treatments for pre-natal and pediatric HIV/AIDS patients, subsequently
developing a Preventive HIV Vaccine. The U.S. Patent office has granted full
patent rights for IPF under patent number 7479538. Efforts are done to
complete the pre-clinical studies in order to position the company's
regulatory efforts in obtaining approval to initiate clinical phase I studies
projected to start the 4th quarter of 2010. The company is in preparation to
initiate efforts of acquiring fast track status designation from the FDA.

This news release contains forward-looking statements that involve risks and
uncertainties associated with financial projections, budgets, milestone
timelines, clinical development, regulatory approvals, and other risks
described by Immunotech Laboratories, Inc. from time to time in its periodic
reports filed with the SEC. IPF is not approved by the US Food and Drug
Administration or by any comparable regulatory agencies elsewhere in the
world. While Immunotech Laboratories believes that the forward-looking
statements and underlying assumptions contained therein are reasonable, any of
the assumptions could be inaccurate, including, but not limited to, the
ability of Immunotech Laboratories to establish the efficacy of IPF in the
treatment of any disease or health condition, the development of studies and
strategies leading to commercialization of IPF in the United States, the
obtaining of funding required to carry out the development plan, the
completion of studies and tests on time or at all, and the successful outcome
of such studies or tests. Therefore, there can be no assurance that the
forward-looking statements included in this release will prove to be accurate.
In light of the significant uncertainties inherent in the forward-looking
statements included herein, Immunotech Laboratories or any other person that
the objectives and plans of Immunotech Laboratories will be achieved should
not regard the forward-looking statements as a representation.

Ara Ghanime
Chairman of the Board
Contact Number (818) 409-9091

SOURCE Immunotech Laboratories, Inc.

Ara Ghanime, Chairman of the Board of Immunotech Laboratories, Inc.,
+1-818-409-9091